Small Molecule Antagonists Of The Pro-Survival Protein Mcl-1
- 技术优势
- Direct inhibition of the MCL-1 proteinSmall molecule inhibitor
- 技术应用
- Therapeutic approach to activate the apoptosis pathway, potentially leading to cancer cell deathPotentially used as a combination therapy, or as a monotherapy
- 详细技术说明
- UCLA Researchers in the Department Chemistry & Biochemistry have developed novel small molecules that bind MCL-1, which in turn promotes the activation of the apoptosis pathway, resulting in cancer cell death.
- *Abstract
-
UCLA Researchers have discovered novel inhibitors to signaling proteins involved in the regulation of apoptosis. MCL-1, which is known to be overexpressed in many cancers, is believed to be upregulated in cancers to prevent the apoptosis pathway.The researchers have developed novel small molecules that inhibit this protein, triggering apoptosis and cancer cell death.
- *IP Issue Date
- Mar 9, 2017
- *Principal Investigation
-
Name: James Frederich
Department:
Name: Patrick Harran
Department:
Name: Mai Nguyen
Department:
Name: Gordon Shore
Department:
- 申请号码
- 2017066747
- 其他
-
State Of Development
Successful demonstration in vitro binding of recombinant protein
Background
Multiple cancer types, including chronic lymphocytic leukemia (CML) have been shown to overexpress signaling proteins involved the inhibition of apoptosis, including BCL-2 and MCL-1.This feature makes these proteins ideal targets for cancer therapeutics.Currently, there is one small molecule that has been FDA approved that targets this signaling pathway, binding to BCL-2.However, 60% of patients each year are resistant to this treatment, highlighting the necessity of targeting other proteins within this pathway, such as MCL-1.
Related Materials
Tech ID/UC Case
27303/2014-387-0
Related Cases
2014-387-0
- 国家/地区
- 美国
